241 related articles for article (PubMed ID: 26332828)
1. Innate Immune Signalling Genetics of Pain, Cognitive Dysfunction and Sickness Symptoms in Cancer Pain Patients Treated with Transdermal Fentanyl.
Barratt DT; Klepstad P; Dale O; Kaasa S; Somogyi AA
PLoS One; 2015; 10(9):e0137179. PubMed ID: 26332828
[TBL] [Abstract][Full Text] [Related]
2. Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study.
Barratt DT; Bandak B; Klepstad P; Dale O; Kaasa S; Christrup LL; Tuke J; Somogyi AA
Pharmacogenet Genomics; 2014 Apr; 24(4):185-94. PubMed ID: 24469018
[TBL] [Abstract][Full Text] [Related]
3. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
4. Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients.
Radbruch L; Sabatowski R; Petzke F; Brunsch-Radbruch A; Grond S; Lehmann KA
Palliat Med; 2001 Jul; 15(4):309-21. PubMed ID: 12054148
[TBL] [Abstract][Full Text] [Related]
5. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
[TBL] [Abstract][Full Text] [Related]
6. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain.
Tawfik MO; Bryuzgin V; Kourteva G;
Curr Med Res Opin; 2004 Mar; 20(3):259-67. PubMed ID: 15025835
[TBL] [Abstract][Full Text] [Related]
7. Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain.
Somogyi AA; Sia AT; Tan EC; Coller JK; Hutchinson MR; Barratt DT
Pain; 2016 Nov; 157(11):2458-2466. PubMed ID: 27649267
[TBL] [Abstract][Full Text] [Related]
8. Opioid plasma concentrations during a switch from transdermal fentanyl to methadone.
Mercadante S; Villari P; Ferrera P; Casuccio A; Gambaro V
J Palliat Med; 2007 Apr; 10(2):338-44. PubMed ID: 17472504
[TBL] [Abstract][Full Text] [Related]
9. Transdermal fentanyl in opioid-naive cancer pain patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine.
Vielvoye-Kerkmeer AP; Mattern C; Uitendaal MP
J Pain Symptom Manage; 2000 Mar; 19(3):185-92. PubMed ID: 10760623
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and predictors of cognitive dysfunction in opioid-treated patients with cancer: a multinational study.
Kurita GP; Sjøgren P; Ekholm O; Kaasa S; Loge JH; Poviloniene I; Klepstad P
J Clin Oncol; 2011 Apr; 29(10):1297-303. PubMed ID: 21357785
[TBL] [Abstract][Full Text] [Related]
11. Rapid switching between transdermal fentanyl and methadone in cancer patients.
Mercadante S; Ferrera P; Villari P; Casuccio A
J Clin Oncol; 2005 Aug; 23(22):5229-34. PubMed ID: 16051965
[TBL] [Abstract][Full Text] [Related]
12. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
[TBL] [Abstract][Full Text] [Related]
13. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
14. Predicting long-term response to strong opioids in patients with low back pain: findings from a randomized, controlled trial of transdermal fentanyl and morphine.
Kalso E; Simpson KH; Slappendel R; Dejonckheere J; Richarz U
BMC Med; 2007 Dec; 5():39. PubMed ID: 18154644
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of transdermal buprenorphine and transdermal fentanyl in the treatment of neuropathic pain in AIDS patients.
Canneti A; Luzi M; Di Marco P; Cannata F; Pasqualitto F; Spinoglio A; Reale C
Minerva Anestesiol; 2013 Aug; 79(8):871-83. PubMed ID: 23558760
[TBL] [Abstract][Full Text] [Related]
16. Transdermal fentanyl in cachectic cancer patients.
Heiskanen T; Mätzke S; Haakana S; Gergov M; Vuori E; Kalso E
Pain; 2009 Jul; 144(1-2):218-22. PubMed ID: 19442446
[TBL] [Abstract][Full Text] [Related]
17. [Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain].
Hata A; Katakami N; Masuda Y; Nanjo S; Otsuka K; Kaji R; Fujita S; Iwamori S; Mifune Y; Orita H; Fukae M; Yamatani T
Gan To Kagaku Ryoho; 2011 Mar; 38(3):415-8. PubMed ID: 21403444
[TBL] [Abstract][Full Text] [Related]
18. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial.
Mystakidou K; Befon S; Kouskouni E; Gerolymatos K; Georgaki S; Tsilika E; Vlahos L
Anticancer Res; 2001; 21(3C):2225-30. PubMed ID: 11501851
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
Clark AJ; Ahmedzai SH; Allan LG; Camacho F; Horbay GL; Richarz U; Simpson K
Curr Med Res Opin; 2004 Sep; 20(9):1419-28. PubMed ID: 15383190
[TBL] [Abstract][Full Text] [Related]
20. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
Sittl R; Nuijten M; Nautrup BP
Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
